These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

626 related items for PubMed ID: 19201878

  • 1. A synthetic carbohydrate-protein conjugate vaccine candidate against Shigella flexneri 2a infection.
    Phalipon A, Tanguy M, Grandjean C, Guerreiro C, Bélot F, Cohen D, Sansonetti PJ, Mulard LA.
    J Immunol; 2009 Feb 15; 182(4):2241-7. PubMed ID: 19201878
    [Abstract] [Full Text] [Related]

  • 2. Characterization of functional oligosaccharide mimics of the Shigella flexneri serotype 2a O-antigen: implications for the development of a chemically defined glycoconjugate vaccine.
    Phalipon A, Costachel C, Grandjean C, Thuizat A, Guerreiro C, Tanguy M, Nato F, Vulliez-Le Normand B, Bélot F, Wright K, Marcel-Peyre V, Sansonetti PJ, Mulard LA.
    J Immunol; 2006 Feb 01; 176(3):1686-94. PubMed ID: 16424198
    [Abstract] [Full Text] [Related]

  • 3. Rational design and immunogenicity of liposome-based diepitope constructs: application to synthetic oligosaccharides mimicking the Shigella flexneri 2a O-antigen.
    Said Hassane F, Phalipon A, Tanguy M, Guerreiro C, Bélot F, Frisch B, Mulard LA, Schuber F.
    Vaccine; 2009 Aug 27; 27(39):5419-26. PubMed ID: 19559116
    [Abstract] [Full Text] [Related]

  • 4. Safety and immunogenicity of a synthetic carbohydrate conjugate vaccine against Shigella flexneri 2a in healthy adult volunteers: a phase 1, dose-escalating, single-blind, randomised, placebo-controlled study.
    Cohen D, Atsmon J, Artaud C, Meron-Sudai S, Gougeon ML, Bialik A, Goren S, Asato V, Ariel-Cohen O, Reizis A, Dorman A, Hoitink CWG, Westdijk J, Ashkenazi S, Sansonetti P, Mulard LA, Phalipon A.
    Lancet Infect Dis; 2021 Apr 27; 21(4):546-558. PubMed ID: 33186516
    [Abstract] [Full Text] [Related]

  • 5. Safety and immunogenicity of Shigella sonnei-CRM9 and Shigella flexneri type 2a-rEPAsucc conjugate vaccines in one- to four-year-old children.
    Passwell JH, Ashkenazi S, Harlev E, Miron D, Ramon R, Farzam N, Lerner-Geva L, Levi Y, Chu C, Shiloach J, Robbins JB, Schneerson R, Israel Shigella Study Group.
    Pediatr Infect Dis J; 2003 Aug 27; 22(8):701-6. PubMed ID: 12913770
    [Abstract] [Full Text] [Related]

  • 6. Immunogenicity and protective efficacy offered by a ribosomal-based vaccine from Shigella flexneri 2a.
    Shim DH, Chang SY, Park SM, Jang H, Carbis R, Czerkinsky C, Uematsu S, Akira S, Kweon MN.
    Vaccine; 2007 Jun 15; 25(25):4828-36. PubMed ID: 17507120
    [Abstract] [Full Text] [Related]

  • 7. Construction of a multivalent vaccine strain of Shigella flexneri and evaluation of serotype-specific immunity.
    Jennison AV, Roberts F, Verma NK.
    FEMS Immunol Med Microbiol; 2006 Apr 15; 46(3):444-51. PubMed ID: 16553820
    [Abstract] [Full Text] [Related]

  • 8. Development of a Shigella conjugate vaccine targeting Shigella flexneri 6 that is immunogenic and provides protection against virulent challenge.
    Kelly M, Janardhanan J, Wagh C, Verma S, Charles RC, Leung DT, Kamruzzaman M, Pansuriya RK, Chowdhury F, Vann WF, Kaminski RW, Khan AI, Bhuiyan TR, Qadri F, Kováč P, Xu P, Ryan ET.
    Vaccine; 2024 Oct 24; 42(24):126263. PubMed ID: 39217775
    [Abstract] [Full Text] [Related]

  • 9. Safety and immunogenicity of Shigella sonnei and Shigella flexneri 2a O-specific polysaccharide conjugates in children.
    Ashkenazi S, Passwell JH, Harlev E, Miron D, Dagan R, Farzan N, Ramon R, Majadly F, Bryla DA, Karpas AB, Robbins JB, Schneerson R.
    J Infect Dis; 1999 Jun 24; 179(6):1565-8. PubMed ID: 10228084
    [Abstract] [Full Text] [Related]

  • 10. Induction of anti-carbohydrate antibodies by phage library-selected peptide mimics.
    Phalipon A, Folgori A, Arondel J, Sgaramella G, Fortugno P, Cortese R, Sansonetti PJ, Felici F.
    Eur J Immunol; 1997 Oct 24; 27(10):2620-5. PubMed ID: 9368618
    [Abstract] [Full Text] [Related]

  • 11. Regulated Delayed Shigella flexneri 2a O-antigen Synthesis in Live Recombinant Salmonella enterica Serovar Typhimurium Induces Comparable Levels of Protective Immune Responses with Constitutive Antigen Synthesis System.
    Su H, Liu Q, Wang S, Curtiss R, Kong Q.
    Theranostics; 2019 Oct 24; 9(12):3565-3579. PubMed ID: 31281498
    [Abstract] [Full Text] [Related]

  • 12. Development and evaluation of a Shigella flexneri 2a and S. sonnei bivalent invasin complex (Invaplex) vaccine.
    Oaks EV, Turbyfill KR.
    Vaccine; 2006 Mar 20; 24(13):2290-301. PubMed ID: 16364513
    [Abstract] [Full Text] [Related]

  • 13. Safety and Immunogenicity of a Candidate Bioconjugate Vaccine against Shigella flexneri 2a Administered to Healthy Adults: a Single-Blind, Randomized Phase I Study.
    Riddle MS, Kaminski RW, Di Paolo C, Porter CK, Gutierrez RL, Clarkson KA, Weerts HE, Duplessis C, Castellano A, Alaimo C, Paolino K, Gormley R, Gambillara Fonck V.
    Clin Vaccine Immunol; 2016 Dec 20; 23(12):908-917. PubMed ID: 27581434
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Vaccination with Shigella flexneri 2a conjugate induces type 2a and cross-reactive type 6 antibodies in humans but not in mice.
    Farzam N, Ramon-Saraf R, Banet-Levi Y, Lerner-Geva L, Ashkenazi S, Kubler-Kielb J, Vinogradov E, Robbins JB, Schneerson R.
    Vaccine; 2017 Sep 05; 35(37):4990-4996. PubMed ID: 28797729
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 32.